×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MRSN – mersana therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MRSN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/15
09:08 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $5.00 price target on the stock.
High
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $5.00 price target on the stock.
11/14
02:21 am
mrsn
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Low
Report
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
11/13
07:00 am
mrsn
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
High
Report
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results
11/6
08:00 am
mrsn
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
High
Report
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024
10/15
03:40 pm
mrsn
SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc [Yahoo! Finance]
Low
Report
SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc [Yahoo! Finance]
8/27
10:55 am
mrsn
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target lowered by analysts at Citigroup Inc. from $6.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Mersana Therapeutics, Inc. (NASDAQ: MRSN) had its price target lowered by analysts at Citigroup Inc. from $6.00 to $5.00. They now have a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2024
07:00 am
MRSN
mersana therapeutics, inc.
BEAT
Report
19.5%
mersana therapeutics, inc.
8/13/2024
07:00 am
MRSN
mersana therapeutics, inc.
MISS
Report
-3.6%
mersana therapeutics, inc.
5/9/2024
06:59 am
MRSN
mersana therapeutics, inc.
BEAT
Report
-30.2%
mersana therapeutics, inc.
2/28/2024
07:00 am
MRSN
mersana therapeutics, inc.
BEAT
Report
13.6%
mersana therapeutics, inc.
Date
Time
Symbol
Headline
Impact
11/15
04:46 pm
mrsn
Form SC 13D/A Mersana Therapeutics, Filed by: Bain Capital Life Sciences Fund II, L.P.
Medium
Report
Form SC 13D/A Mersana Therapeutics, Filed by: Bain Capital Life Sciences Fund II, L.P.
11/14
05:46 pm
mrsn
Form SC 13G/A Mersana Therapeutics, Filed by: Nextech Crossover I GP S.a r.l.
Medium
Report
Form SC 13G/A Mersana Therapeutics, Filed by: Nextech Crossover I GP S.a r.l.
11/14
06:04 am
mrsn
Form SC 13G/A Mersana Therapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
Medium
Report
Form SC 13G/A Mersana Therapeutics, Filed by: BALYASNY ASSET MANAGEMENT L.P.
11/13
08:51 am
mrsn
Form 10-Q Mersana Therapeutics, For: Sep 30
Medium
Report
Form 10-Q Mersana Therapeutics, For: Sep 30
11/13
07:27 am
mrsn
Form 8-K Mersana Therapeutics, For: Nov 13
Medium
Report
Form 8-K Mersana Therapeutics, For: Nov 13
10/29
04:44 pm
mrsn
Form 4 Mersana Therapeutics, For: Oct 25 Filed by: Bala Mohan
Medium
Report
Form 4 Mersana Therapeutics, For: Oct 25 Filed by: Bala Mohan
10/29
04:27 pm
mrsn
Form 144 Mersana Therapeutics, Filed by: Bala Mohan
Medium
Report
Form 144 Mersana Therapeutics, Filed by: Bala Mohan
10/15
06:56 am
mrsn
Form SC 13G/A Mersana Therapeutics, Filed by: SILVERARC CAPITAL MANAGEMENT, LLC
Medium
Report
Form SC 13G/A Mersana Therapeutics, Filed by: SILVERARC CAPITAL MANAGEMENT, LLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/8
Mersana Therapeutics secures $65M capital raise [Seeking Alpha]
33.5%
1/16 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 22.7%
2/8 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 14.9%
11/27 Form 8-K Mersana Therapeutics, For: Nov 26 12.6%
2/28 Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.7%
2/18 Mersana Therapeutics to Present at Upcoming Investor Conferences 9.1%
12/23 Form SC 13G Mersana Therapeutics, Filed by: Venrock Healthcare Capital Partners II, L.P. 9.1%
5/9 Form 10-Q Mersana Therapeutics, For: Mar 31 8.3%
10/10 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.1%
11/6 Form 8-K Mersana Therapeutics, For: Nov 06 7.0%
1/16 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 22.7%
2/8 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 14.9%
11/27 Form 8-K Mersana Therapeutics, For: Nov 26 12.6%
2/28 Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] 10.7%
2/18 Mersana Therapeutics to Present at Upcoming Investor Conferences 9.1%
12/23 Form SC 13G Mersana Therapeutics, Filed by: Venrock Healthcare Capital Partners II, L.P. 9.1%
5/9 Form 10-Q Mersana Therapeutics, For: Mar 31 8.3%
10/10 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.1%
11/6 Form 8-K Mersana Therapeutics, For: Nov 06 7.0%
TOP News Decliners
3/30
Form 8-K Mersana Therapeutics, For: Mar 30
-15.5%
3/14 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.50 price target on the stock. -13.8%
12/28 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -12.8%
3/12 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.7%
8/10 Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.3%
4/9 Form 424B5 Mersana Therapeutics, -9.1%
4/29 Mersana Therapeutics to Host Conference Call Announcing First Quarter 2020 Financial Results and Business Updates -8.9%
4/20 Form DEF 14A Mersana Therapeutics, For: Jun 12 -8.8%
6/1 Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting -8.1%
6/12 Form 8-K Mersana Therapeutics, For: Jun 07 -7.8%
3/14 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $6.50 price target on the stock. -13.8%
12/28 Mersana Therapeutics Inc (NASDAQ: MRSN) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. -12.8%
3/12 Mersana Therapeutics Inc (NASDAQ: MRSN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -10.7%
8/10 Mersana Therapeutics, Inc. (MRSN) CEO Anna Protopapas on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.3%
4/9 Form 424B5 Mersana Therapeutics, -9.1%
4/29 Mersana Therapeutics to Host Conference Call Announcing First Quarter 2020 Financial Results and Business Updates -8.9%
4/20 Form DEF 14A Mersana Therapeutics, For: Jun 12 -8.8%
6/1 Mersana Presents Interim Phase 1 Data for XMT-1536 at the 2019 American Society of Clinical Oncology Annual Meeting -8.1%
6/12 Form 8-K Mersana Therapeutics, For: Jun 07 -7.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: